Cefiderocol

Edina Avdic, Pharm.D.
Pediatric Dosing Author: Bethany Sharpless Chalk, Pharm.D., BCPPS

INDICATIONS

FDA

Patients ≥18 y/o for the treatment of the following infections caused by susceptible Gram-negative microorganisms:
- Complicated urinary tract infections (cUTI), including pyelonephritis
- Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP)

NON-FDA APPROVED USES

MDR GNR (e.g. Pseudomonas, Acinetobacter, CRO) infections when no other alternatives are available

There's more to see -- the rest of this topic is available only to subscribers.

© 2000–2025 Unbound Medicine, Inc. All rights reserved

All content is protected by copyright and may not be used for AI model training or other unauthorized purposes.